Immatics Biotechnologies GmbH has entered into a research collaboration and license agreement with Genmab A/S to develop next-generation, T-cell engaging bispecific immunotherapies targeting multiple cancer indications. The companies will conduct joint research, funded by Genmab, to combine Immatics’ XPRESIDENT® and Bispecific TCR technology platforms with Genmab’s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The companies will exclusively disc...